Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: API Import to Russia (November 2018)

Monday, January 21, 2019

Between January and November 2018, Russia imported 86.7 bln RUB worth of APIs (free circulation prices, VAT included), which is in monetary terms 29.3% lower than that of the same period of 2017. In physical terms, Russia imported 10,600 tons of APIs, which is 5% lower than that of the same period of 2017.

The dynamics of the import of pharmacopoeial APIs over the period in monetary terms are +29.5%, while those of the import of technical APIs are +22%. The dynamics in physical terms are -4.6% and -11%, respectively.

The total number of importers of pharmacopoeial APIs over the period is 502, which is 31 company higher than that in 2017. As for technical APIs, the total number is 99, which is six companies lower than that in 2017.

Among the top 15 companies with the biggest import volume of pharmacopoeial APIs in monetary terms, Novo Nordisk has the highest dynamics (a 241 times increase.) The company has been importing only 4 APIs to Russia, its Insulin Detemir and Insulin Aspart (imported since March 2018) amount to 64% and 35% of the import, respectively. The production of both APIs is fully localized at the company’s facilities in the Kaluga region. As for technical APIs, Yantai Biofengs Pharm-Tech started to import its 4 APIs in March 2018, and it has already landed 3rd in import volume in monetary terms. The company’s only partner in Russia is Pharmasyntez, which produces anti-tumor Imatinib, Capecitabine, Darbines (Fludarabine), and Letrozole.

Read more about API import to Russia (October 2018 results) here: http://rncph.com/news/24_12_2018

Dynamics of pharmacopoeial and technical API import to Russia, customs clearance prices (2015 – 2017, January – November 2018), bln RUB

Share: